PT  - JOURNAL ARTICLE
AU  - B L Browning
AU  - V Annese
AU  - M L Barclay
AU  - S A Bingham
AU  - S Brand
AU  - C Büning
AU  - M Castro
AU  - S Cucchiara
AU  - B Dallapiccola
AU  - H Drummond
AU  - L R Ferguson
AU  - A Ferraris
AU  - S A Fisher
AU  - R B Gearry
AU  - J Glas
AU  - L Henckaerts
AU  - C Huebner
AU  - D Knafelz
AU  - L Lakatos
AU  - P L Lakatos
AU  - A Latiano
AU  - X Liu
AU  - C Mathew
AU  - B Müller-Myhsok
AU  - W G Newman
AU  - E R Nimmo
AU  - C L Noble
AU  - O Palmieri
AU  - M Parkes
AU  - I Petermann
AU  - P Rutgeerts
AU  - J Satsangi
AU  - A N Shelling
AU  - K A Siminovitch
AU  - H-P Török
AU  - M Tremelling
AU  - S Vermeire
AU  - M R Valvano
AU  - H Witt
TI  - Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts
AID  - 10.1136/jmg.2007.050773
DP  - 2008 Jan 01
TA  - Journal of Medical Genetics
PG  - 36--42
VI  - 45
IP  - 1
4099  - http://jmg.bmj.com/content/45/1/36.short
4100  - http://jmg.bmj.com/content/45/1/36.full
SO  - J Med Genet2008 Jan 01; 45
AB  - Background: DLG5 p.R30Q has been reported to be associated with Crohn disease (CD), but this association has not been replicated in most studies. A recent analysis of gender-stratified data from two case–control studies and two population cohorts found an association of DLG5 30Q with increased risk of CD in men but not in women and found differences between 30Q population frequencies for males and females. Male–female differences in population allele frequencies and male-specific risk could explain the difficulty in replicating the association with CD.Methods: DLG5 R30Q genotype data were collected for patients with CD and controls from 11 studies that did not include gender-stratified allele counts in their published reports and tested for male–female frequency differences in controls and for case–control frequency differences in men and in women.Results: The data showed no male–female allele frequency differences in controls. An exact conditional test gave marginal evidence that 30Q is associated with decreased risk of CD in women (p = 0.049, OR = 0.87, 95% CI 0.77 to 1.00). There was also a trend towards reduced 30Q frequencies in male patients with CD compared with male controls, but this was not significant at the 0.05 level (p = 0.058, OR = 0.87, 95% CI 0.74 to 1.01). When data from this study were combined with previously published, gender-stratified data, the 30Q allele was found to be associated with decreased risk of CD in women (p = 0.010, OR = 0.86, 95% CI 0.76 to 0.97), but not in men.Conclusion: DLG5 30Q is associated with a small reduction in risk of CD in women.